Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472693 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00472693 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 5 participants.
The verdict
NCT00472693, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
Interventions
- DRUG Bevacizumab, Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472693
The ClinicalTrials.gov registry entry for NCT00472693 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab, Abraxane is the first listed.
NCT00472693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472693 about?
NCT00472693 is a clinical study titled "Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer". The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
What is the current status of trial NCT00472693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2007-05. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00472693?
The interventions under investigation include: Bevacizumab, Abraxane (DRUG).
Who is sponsoring clinical trial NCT00472693?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.